CIK 0001069899
- Large accelerated filer
PHIBRO ANIMAL HEALTH CORP
Sign in to watch- Ticker
- PAHC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 131840497
- Phone
- +1 201-329-7300
- Business address
- GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., SUITE 21, TEANECK, NJ, 07666
- Former names
- PHILIPP BROTHERS CHEMICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-06 | David Glenn Chief Financial Officer | Grant or award | +3,482 | 54,959 | ||
| 2026-08-06 | David Glenn Chief Financial Officer | Grant or award | +3,334 | 54,811 | ||
| 2026-08-04 | David Glenn Chief Financial Officer | Other disposition | −840 | $36.60 | $31K | 51,477 |
| 2026-02-11 | David Glenn Chief Financial Officer | Other disposition | −12,528 | $51.63 | $647K | 52,317 |
| 2026-02-09 | David Glenn Chief Financial Officer | Exercise or conversion | +30,000 | 64,845 | ||
| 2026-02-09 | David Glenn Chief Financial Officer | Exercise or conversion · Restricted Stock Units | −30,000 | 240,000 | ||
| 2025-08-15 | David Glenn Chief Financial Officer | Grant or award | +4,845 | 34,845 | ||
| 2025-02-09 | David Glenn Chief Financial Officer | Exercise or conversion | +30,000 | 30,000 | ||
| 2025-02-09 | David Glenn Chief Financial Officer | Exercise or conversion · Restricted Stock Units | −30,000 | 270,000 | ||
| 2024-02-09 | David Glenn Chief Financial Officer | Grant or award · Restricted Stock Units | +300,000 | 300,000 |
Page 1 of 1 · 10 trades